- Home
- GPRK vs VNDA Comparison
GPRK vs VNDA Comparison
Compare GPRK & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPRK | VNDA |
|---|---|---|
| Founded | 2002 | 2002 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.8M | 474.0M |
| IPO Year | 2009 | 2005 |
Fundamental Metrics
Financial Performance| Metric | GPRK | VNDA |
|---|---|---|
| Price | $9.45 | $6.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.50 | ★ $14.90 |
| AVG Volume (30 Days) | 1.4M | ★ 1.7M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.24% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $216,105,000.00 |
| Revenue This Year | $39.45 | $21.35 |
| Revenue Next Year | N/A | $37.40 |
| P/E Ratio | $12.70 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $5.66 | $3.81 |
| 52 Week High | $10.34 | $9.91 |
Technical Indicators
Market Signals| Indicator | GPRK | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 40.46 |
| Support Level | $7.84 | $4.36 |
| Resistance Level | $10.34 | $8.29 |
| Average True Range (ATR) | 0.44 | 0.50 |
| MACD | -0.02 | -0.22 |
| Stochastic Oscillator | 50.56 | 9.56 |
Price Performance
Historical ComparisonAbout GPRK Geopark Ltd
GeoPark Ltd is a Latin American oil and gas exploration and production company with assets in Colombia, Ecuador, Chile, Brazil, and Argentina. The company generates revenue from the sale of crude oil, condensate, and natural gas, net of value-added tax and discounts related to the sale and overriding royalties due to the ex-owners of oil and gas properties where the royalty arrangements represent a retained working interest in the property.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.